Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial on the Tolerability and Pharmacokinetics of Recombinant Humanized Anti-PD-L1 Monoclonal Antibody MSB2311 Injection in the Treatment of Patients With Advanced Solid Tumors

NCT04272944 is registered in ClinicalTrials.gov with Suzhou Transcenta Therapeutics Co., Ltd. as lead sponsor.

NCT NCT04272944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04272944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial on the Tolerability and Pharmacokinetics of Recombinant Humanized Anti-PD-L1 Monoclonal Antibody MSB2311 Injection in the Treatment of Patients With Advanced Solid Tumors
Lead sponsor
Suzhou Transcenta Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
August 13, 2018
Completion date
January 31, 2022
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor